Lucid Diagnostics company info

What does Lucid Diagnostics do?
Lucid Diagnostics (NASDAQ:LUCD) specializes in developing and commercializing innovative and non-invasive diagnostic tests for early detection of esophageal cancer, a critical focus given the growing prevalence of this condition. The company is dedicated to transforming the landscape of esophageal health by offering accessible and reliable solutions aimed at identifying precancerous conditions before they evolve into more severe stages. With a strong commitment to research and innovation, Lucid Diagnostics is actively involved in advancing its portfolio of diagnostic tools, with projects aimed at expanding usage and improving the accuracy of esophageal cancer detection. The company's objective is to significantly reduce the mortality rate associated with esophageal cancer by making early detection more common, aiding in the timely treatment and management of the disease.
Lucid Diagnostics company media
Company Snapshot

Is Lucid Diagnostics a public or private company?

key
Ownership
Public

How many people does Lucid Diagnostics employ?

people
Employees
70

What sector is Lucid Diagnostics in?

pie chart
Sector
Health Care

Where is the head office for Lucid Diagnostics?

location pin
Head Office
New York, United States

What year was Lucid Diagnostics founded?

founded flag
Year Founded
2018
What does Lucid Diagnostics specialise in?
/Medical Diagnostics /EsoGuard Test /EsoCheck Device /DNA Methylation /Esophageal Cancer /Preventive Screening

What are the products and/or services of Lucid Diagnostics?

Overview of Lucid Diagnostics offerings
EsoGuard, a DNA test designed to detect esophageal precancerous conditions with high sensitivity.
EsoCheck, a non-invasive, office-based procedure used alongside EsoGuard for sampling of esophageal cells.
EsoCure, an esophageal ablation device with pending FDA approval aimed at treating precancerous esophageal conditions.
LucidDx Labs, a dedicated laboratory service that processes EsoGuard and other diagnostic tests.
Research partnerships focused on advancing the detection and treatment of esophageal diseases, including precancerous conditions.
Educational initiatives aimed at raising awareness about the risks of esophageal cancer and the importance of early detection.

Who is in the executive team of Lucid Diagnostics?

Lucid Diagnostics leadership team
  • Dr. Lishan  Aklog M.D.
    Dr. Lishan Aklog M.D.
    Chairman & CEO
  • Mr. Shaun M. O'Neill M.B.A.
    Mr. Shaun M. O'Neill M.B.A.
    President & COO
  • Mr. Dennis M. McGrath CPA
    Mr. Dennis M. McGrath CPA
    Chief Financial Officer
  • Dr. Sanford D. Markowitz M.D., Ph.D.
    Dr. Sanford D. Markowitz M.D., Ph.D.
    Cofounder & Strategic Advisor, Member of the Medical Advisor Board
  • Dr. Joseph  Willis M.D.
    Dr. Joseph Willis M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Dr. Amitabh  Chak M.D.
    Dr. Amitabh Chak M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Richard D. Yazbeck
    Richard D. Yazbeck
    Chief Technology Officer
  • Dr. Suman M. Verma M.D., Ph.D.
    Dr. Suman M. Verma M.D., Ph.D.
    Chief Scientific Officer